report_lead_image_with_gradient.png
Q1 2025

Pharma Biotools VC Trends

Download this Report
To download this report, please complete the form below

Fill out the form to download a preview of this report. The full report and its Excel data pack are available through the PitchBook Platform.

Pharma biotools funding surges in Q1 2025 led by AI and synthetic biology platforms

VC investment in pharma biotools rebounded strongly in Q1 2025, showing significant increases in both funding and deal count. This quarter represented the highest funding level since Q2 2024, with trailing 12-month funding demonstrating robust YoY growth despite broader market consolidation pressures.

Key investment trends:

  • Synthetic biology and AI platforms dominate megarounds: Colossal Biosciences secured a $200 million Series C for its CRISPR-based de-extinction platform, while AI-driven drug discovery platforms like Chai Discovery and Bioptimus attracted $60 million and $41.4 million, respectively.
  • Spatial biology and multiomics tools gain momentum: Stellaromics’ $80 million Series B for its gene expression analysis technology and Quibim’s $50 million Series A for its precision health imaging technology highlight growing investor interest in next-generation analytical platforms.
  • Exit activity remains constrained with strategic M&A dominating: While exit activity remained low, strategic acquisitions and multiple genomics platform acquisitions by established players demonstrated continued consolidation interest.

Table of contents
Pharma biotools landscape 3
Pharma biotools VC ecosystem market map 4
Pharma biotools VC activity 5
Pharma biotools VC deal summary 17